Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
double-loaded dendritic cell therapy
- Development stage
- Unknown
- Lead developer
- Diakonos Oncology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Double-loaded dendritic cell therapy (DOC1021) is a personalized autologous cancer immunotherapy developed by Diakonos Oncology. The platform utilizes a unique 'double-loading' technique where patient-derived dendritic cells are simultaneously pulsed with both tumor lysate and tumor-derived mRNA. This dual-loading strategy is designed to mimic a viral infection, programming both MHC class I and MHC class II pathways to trigger a robust and comprehensive immune response involving both CD8+ cytotoxic T cells and CD4+ helper T cells. By targeting a broad spectrum of patient-specific tumor-associated antigens (uTAAs), the therapy aims to overcome the limitations of single-antigen vaccines. It is currently being evaluated in clinical trials for glioblastoma, ovarian cancer, and acute myeloid leukemia (AML), and is administered via injection near lymph nodes to facilitate rapid migration to the immune system.
- Other names
- DOC-1021DOC1021DOC 1021Immunocine Dendritic Cell Treatment
Beyond the preview
Go deeper on double-loaded dendritic cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on double-loaded dendritic cell therapy.